Vertex expands CASGEVY to young children with sickle cell disease and beta thalassemia
Explore how the FDA’s CASGEVY age expansion could reshape early gene therapy for sickle cell disease and beta thalassemia. Read more.
Pharma & Biotech
Pharma & Biotech
Scribe Therapeutics deepens in vivo CRISPR validation with second Eli Lilly collaboration milestone
Scribe Therapeutics hits a second in vivo CRISPR milestone with Eli Lilly. Explore what this changes for gene editing platforms and future therapies.
Pharma & Biotech
Can CRISPR editing of NRF2 reverse resistance in head and neck squamous cell carcinoma?
CorriXR’s new data show CRISPR-based NRF2 disruption restores chemo response in squamous tumors. Find out what this could mean for HNSCC treatment.